ArticleDiscover oncology2025
TMT-based proteomics analysis identifies RPLP1 as a key protein target in ursolic acid Inhibition of colorectal cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immune and Tumor Microenvironment Mechanisms ofCancers · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUrsolic Acid (UA), a triterpenoid extracted from Hedyotis Diffusa Willd. (HDW), is known for its anti-inflammatory, antioxidant, and antitumor effects. Nevertheless, the mechanisms underlying UA's anti-colorectal cancer (CRC) effects remain insufficiently understood. This study aimed to identify the key target proteins of UA and investigate their functions in CRC development.
methodsThe cytotoxicity of three active components of HDW (UA, oleanolic acid (OA), and quercetin) on CRC cells was evaluated using the CCK-8 assay. Tandem mass tag (TMT)-based proteomics was employed to detect differentially expressed proteins (DEPs) in CRC cells after UA treatment. Bioinformatics analysis and high-content screening were used to identify UA's key protein targets. The expression and role of RPLP1 in CRC cells were investigated, including the effects of RPLP1 knockdown and its combination with UA treatment on cell proliferation, migration, invasion, and apoptosis.
resultsUA demonstrated superior inhibitory effects on CRC cells compared to OA and quercetin, highlighting it as a principal active ingredient of HDW. TMT-based proteomic analysis identified 438 upregulated and 366 downregulated proteins after UA intervention. Among these, RPLP1 was identified as a critical target. UA inhibited RPLP1 expression in CRC cells, resulting in decreased cell proliferation, migration, and invasion. Furthermore, the combination of UA treatment and RPLP1 knockdown exhibited synergistic effects in inhibiting CRC cell growth and migration, as well as promoting apoptosis.
conclusionsUA, a bioactive triterpenoid of HDW, inhibits CRC development by targeting and suppressing RPLP1 expression. These findings provide novel insights into the therapeutic of UA for CRC and highlight RPLP1 as a promising target for intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.